506 related articles for article (PubMed ID: 27974318)
1. A perspective on chronic kidney disease progression.
Zhong J; Yang HC; Fogo AB
Am J Physiol Renal Physiol; 2017 Mar; 312(3):F375-F384. PubMed ID: 27974318
[TBL] [Abstract][Full Text] [Related]
2. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View.
Lambers Heerspink HJ; Gansevoort RT
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1079-88. PubMed ID: 25887073
[TBL] [Abstract][Full Text] [Related]
3. Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis.
Jiang X; Zhou S; Yao J; Kong X; Cui M
J Nephrol; 2016 Oct; 29(5):653-62. PubMed ID: 26510426
[TBL] [Abstract][Full Text] [Related]
4. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
Dattolo PC; Gallo P; Michelassi S; Paudice N; Cannavò R; Romoli E; Fani F; Tsalouchos A; Mehmetaj A; Ferro G; Sisca S; Pizzarelli F
J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
[TBL] [Abstract][Full Text] [Related]
5. Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View.
Fried LF; Lewis J
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1089-93. PubMed ID: 25887070
[TBL] [Abstract][Full Text] [Related]
6. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
Expert Opin Pharmacother; 2015; 16(10):1449-61. PubMed ID: 26037614
[TBL] [Abstract][Full Text] [Related]
7. An update on the pathomechanisms and future therapies of Alport syndrome.
Noone D; Licht C
Pediatr Nephrol; 2013 Jul; 28(7):1025-36. PubMed ID: 22903660
[TBL] [Abstract][Full Text] [Related]
8. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
9. Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.
Wu PC; Wu CJ; Lin CJ; Pan CF; Chen CY; Huang TM; Wu CH; Lin SL; Chen YM; Chen L; Wu VC; ;
Clin Pharmacol Ther; 2015 Oct; 98(4):442-9. PubMed ID: 26082272
[TBL] [Abstract][Full Text] [Related]
10. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D in chronic kidney disease: new potential for intervention.
Mirković K; van den Born J; Navis G; de Borst MH
Curr Drug Targets; 2011 Jan; 12(1):42-53. PubMed ID: 20795938
[TBL] [Abstract][Full Text] [Related]
12. Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis.
Liu D; Wang LN; Li HX; Huang P; Qu LB; Chen FY
J Int Med Res; 2017 Apr; 45(2):383-398. PubMed ID: 28415944
[TBL] [Abstract][Full Text] [Related]
13. The use of vitamin D analogs is independently associated with the favorable renal prognosis in chronic kidney disease stages 4-5: the CKD-ROUTE study.
Arai Y; Kanda E; Iimori S; Naito S; Noda Y; Kawasaki T; Sato H; Ando R; Sasaki S; Sohara E; Okado T; Rai T; Uchida S
Clin Exp Nephrol; 2017 Jun; 21(3):481-487. PubMed ID: 27344335
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update.
Chen YM; Chiang WC; Lin SL; Tsai TJ
J Biomed Sci; 2017 Nov; 24(1):84. PubMed ID: 29132351
[TBL] [Abstract][Full Text] [Related]
15. Endothelin and endothelin antagonists in chronic kidney disease.
Kohan DE; Barton M
Kidney Int; 2014 Nov; 86(5):896-904. PubMed ID: 24805108
[TBL] [Abstract][Full Text] [Related]
16. Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.
Stock J; Kuenanz J; Glonke N; Sonntag J; Frese J; Tönshoff B; Höcker B; Hoppe B; Feldkötter M; Pape L; Lerch C; Wygoda S; Weber M; Müller GA; Gross O
Pediatr Nephrol; 2017 Jan; 32(1):131-137. PubMed ID: 27402170
[TBL] [Abstract][Full Text] [Related]
17. Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease.
Ekart R; Ferjuc A; Furman B; Gerjevič Š; Bevc S; Hojs R
Ther Apher Dial; 2013 Aug; 17(4):363-7. PubMed ID: 23931872
[TBL] [Abstract][Full Text] [Related]
18. Acute Kidney Injury: Tubular Markers and Risk for Chronic Kidney Disease and End-Stage Kidney Failure.
Tan HL; Yap JQ; Qian Q
Blood Purif; 2016; 41(1-3):144-50. PubMed ID: 26764483
[TBL] [Abstract][Full Text] [Related]
19. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).
Smith ER; Lee D; Cai MM; Tomlinson LA; Ford ML; McMahon LP; Holt SG
Nephrol Dial Transplant; 2013 Jun; 28(6):1569-79. PubMed ID: 23328709
[TBL] [Abstract][Full Text] [Related]
20. Strict blood-pressure control and progression of renal failure in children.
; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
